Sabby Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Sabby Management’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-6	Closed	-$21	–	318
2014 Q3	$21	Buy	6 +1	+20%	+$39	﹤0.01%	251
2014 Q2	$22K	Sell	5 -55	-92%	-$2.65K	﹤0.01%	250
2014 Q1	$293K	Sell	60 -33	-35%	-$1.61K	0.02%	199
2013 Q4	$426K	Buy	93 +4	+4%	+$379	0.03%	157
2013 Q3	$914K	Buy	+89	New	+$9.77K	0.06%	128

Other funds holding IMUC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management's IMUC Position: Q2 2017 in Review

Sabby Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2017, closing a stake of 139,912 shares — an estimated $445K sold.

Sabby Management first reported a position in IMUC in Q4 2013 and held it in 10 quarters. The position peaked at $2.86M in Q1 2015. 16 funds tracked by Wall St. Rank hold IMUC as of Q2 2017.

Sabby Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2017 after selling out during the quarter.
Sabby Management sold 139,912 ImmunoCellular Therapeutics, Ltd. shares in Q2 2017, an estimated $445K.
Sabby Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2013 and held it in 10 quarters.
Sabby Management's ImmunoCellular Therapeutics, Ltd. position peaked at $2.86M in Q1 2015.
16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.